Induction of CD4+ and CD8+ Bordetella pertussis toxin subunit S1 specific T cells by immunization with synthetic peptides

Cellular Immunology

Volumn 196, Issue 2, 1999, Pages 110-121

  Fagerberg, Jan ^a   Askelöf, Per ^c   Wigzell, Hans ^b   Mellstedt, Håkan ^a  

^a Cancer Center Karolinska   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

Bordetella pertussis toxin; Humans; Immunization; Synthetic peptides; T cells

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; IDIOTYPIC ANTIBODY; PERTUSSIS TOXIN; SYNTHETIC PEPTIDE;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CASE REPORT; CELLULAR IMMUNITY; COLORECTAL CANCER; DNA SYNTHESIS INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOFLUORESCENCE; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; PRIORITY JOURNAL;

BORDETELLA PERTUSSIS;

EID: 0032703009     PISSN: 00088749     EISSN: None     Source Type: Journal    
DOI: 10.1006/cimm.1999.1548     Document Type: Article

References (29)

1. Rammensee H.-G., Friede T., Stevanovic S. MHC ligands and peptide motifs: First listing. Immunogenetics. 41:1995;178.
2. Panina-Bordignon P., Tan A., Termijtelen A., Demotz S., Corratin G., Lanzavecchia A. Universal immunogenic T cell epitopes: Promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol. 19:1989;2237.
3. Herrington D. A., Clyde D. F., Losonsky G., Cortesia M., Murphy J. R., Davis J., Baqar S., Felix A. M., Heimer E. P., Gillessen D., Nardin E., Nussenzweig R. S., Nussenzweig V., Hollingdale M. R., Levine M. M. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature. 328:1987;257.
4. Klipstein F. A., Engert R. F., Houghten R. A. Mucosal antitoxin response in volunteers to immunization with a synthetic peptide of Escherichia coli heat-stable enterotoxin. Infect. Immun. 50:1985;328.
5. Kahn J. O., Stites D. P., Scillian J., Murcar N., Stryker R., Volberding P. A., Naylor P. H., Goldstein A. L., Sarin P. S., Simmon V. F., Wang S.-S., Heseltine P., A phase I study of HGP-30 a 30 amino acid subunit of the human immunodeficiency virus (HIV) p17 synthetic peptide analogue sub-unit vaccine in seronegative subjects. AIDS Res. Hum. Retrovir. 8:1992;1321.
6. Millet P., Campbell G. H., Sulzer A. J., Grady K. K., Pohl J., Aikawa M., Collins W. E. Immunogenicity of the Plasmodium falciparum asexual blood-stage synthetic peptide vaccine SPf66. Am. J. Trop. Med. Hyg. 48:1993;424.
7. Bourdette D., Whitham R. H., Chou Y. K., Morrison W. J., Atherton J., Kenny C., Liefeld D., Hashim G. A., Offner H., Vandenbark A. A. Immunity to TCR peptides in multiple sclerosis. I. Successful immunization of patients with synthetic Vβ5.2 and Vβ6.1 CDR2 peptides. J. Immunol. 152:1994;2510.
8. Vitiello A., Ishioka G., Grey H. M., Rose R., Farness P., LaFond R., Yuan L., Chisari F. V., Furze J., Bartholomeuz R. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J. Clin. Invest. 95:1995;341.
9. Mukheriji B., Chakraborty N. G., Yamasaki S., Okino T., Yamase H., Sporn J. R., Kurtzman S. K., Ergin M. T., Ozols J., Meehan J., Mauri F. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. Natl. Acad. Sci. USA. 92:1995;8078.
10. Gorse G. J., Keefer M. C., Belshe R. B., Matthews T. J., Forrest B. D., Hsieh R. H., Koff W. C., Hanson C. V., Dolin R., Weinhold K. J., Frey S. E., Ketter N., Fast P. E. A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. J. Infect. Dis. 173:1996;330.
11. Askelöf P., Rodmalm K., Wrangsell G., Larsson U., Svenson S. B., Cowell J. L., Undén A., Bartfai T. Pretective immunogenicity of two synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1. Proc. Natl. Acad. Sci. USA. 87:1990;1347.
12. Steinitz M., Tamir S., Frödin J.-E., Lefvert A.-K., Mellstedt H. Human monoclonal anti-idiotypic antibodies. I. Establishment of immortalized cell lines from a tumor patient treated with mouse monoclonal antibodies. J. Immunol. 141:1988;3516.
13. Fagerberg J., Steinitz M., Wigzell H., Askelöf P., Mellstedt H. Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients. Proc. Natl. Acad. Sci. USA. 92:1995;4773.
14. 1). II. Is induction of anti-idiotype reactive T cells (T2) of importance for tumor response to mAb therapy. Cancer Immunol. Immunother. 38:1994;149.
15. Askelöf P., Rodmalm K., Abens J., Undén A., Bartfai T. Use of synthetic peptides to map antigenic site of bordetella pertussis toxin subunit S1. J. Infect. Dis. 157:1988;738.
16. Locht C., Keith J. M. Pertussis toxin gene: Nucleotide sequence and genetic organization. Science. 232:1986;1258.
17. Nicosia A., Perugini M., Franzini C., Casagli M. C., Borri M. G., Antoni G., Almoni M., Neri P., Ratti G., Rappuoli R. Cloning and sequencing of the pertussis toxin genes: Open structure and gene duplication. Proc. Natl. Acad. Sci. USA. 83:1986;4631.
18. + subsets. Br. J. Haematol. 96:1997;338.
19. Miller D. L., Alderslade R., Ross E. M. Whooping cough and whooping cough vaccine: The risks and benefits debate. Epidemiol. Rev. 4:1982;1.
20. Greco D., Salmaso S., Mastrantonio P., Giuliano M., Tozzi A. E., Anemona A., Ciofi Degli Atti M. L., Giammanco A., Panel P., Blackwelder W. C., Klein D. L., Wassilak S. G. F. a controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N. Engl. J. Med. 334:1996;341.
21. Gustafsson L., Hallander H. O., Olin P., Reizenstein E., Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N. Engl. J. Med. 334:1996;349.
22. Petersen J. W., Ibsen P. H., Bentzon M. W., Capiau C., Heron I. The cell mediated and humoral immune response to vaccination with acellular and whole cell pertussis vaccine in adult humans. FEMS Microbiol. Immunol. 76:1991;279.
23. Podda A., Nencioni L., De Magistris M. T., Di Tommaso A., Bossu P., Nuti S., Pileri P., Peppoloni S., Bugnoli M., Ruggiero P., Marsili I., D'Errico A., Tagliabue A., Rappuoli R., Metabolic humoral. J. Exp. Med. 172:1990;861.
24. Oksenberg J. R., Judd A. K., Ko C., Lim M., Fernandez R., Schoolnik G. K., Steinman L. MHC-restricted recognition of immunogenic T cell epitopes of pertussis toxin reveals determinants in man distinct from the ADP-ribosylase active site. J. Exp. Med. 168:1988;1855.
25. De Magistris M. T., Romano M., Bartolini A., Rappuoli R., Tagliabue A. Human T cell clones define S1 subunit as the most immunogenic moiety of pertussis toxin and determine its epitope map. J. Exp. Med. 169:1989;1519.
26. Chong P., Zobrist G., Sia C., Loosmore S., Klein M. Identification of T- and B-cell epitopes of the S2 and S2 subunits of pertussis toxin by use of synthetic peptides. Infect. Immun. 60:1992;4640.
27. Petersen J. W., Holm A., Ibsen P. H., Hasløv K., Capiau C., Heron I. Identification of human T-cell epitopes on the S4 subunit of pertussis toxin. Infect. Immun. 60:1992;3962.
28. Yip H. C., Karulin A. Y., Tary-Lehmann M., Hesse M. D., Radeke H., Heeger P. S., Trezza R. P., Heinzel F. P., Forsthuber T., Lehmann P. V. Adjuvant-guided type-1 and type-2 immunity: Infectious/noninfectious dichotomy defines the class of response. J. Immunol. 162:1999;3942.
29. Rock K. L. A new foreign policy: MHC class I molecules monitor the outside world. Immunol. Today. 17:1996;131.